Access practice tools, as well as industry leading news, customizable alerts, dockets, and primary content, including a comprehensive collection of case law, dockets, and regulations. Leverage...
By Peter Leung
The Patent Trial and Appeal Board, the patent office body that decides validity challenges, Jan. 10 selected two decisions to provide guidance on petition-filing deadlines.
Both earlier decisions—designated as informative—concern the time bar for filing inter partes reviews, which give challengers a relatively quick way to attack patents outside of court. Challengers that have been sued for infringement must file their IPRs within a year of being served with a complaint. Informative decisions, though not binding, are influential.
The designations follow a U.S. Court of Appeals for the Federal Circuit opinion holding that decisions regarding the one-year time bar can be appealed in court. PTAB decisions on whether to institute trial in IPRs are generally not appealable, but the full Federal Circuit’s ruling in Wi-2 Fi One, LLC v. Broadcom Corp. is an exception to that rule.
In Luv’n Care Ltd v. McGinley, the PTAB refused to take up the IPR because the challenger, even though it filed its petition before the one-year deadline, didn’t pay the required filing fees until after.
Luv’n Care Ltd., which challenged a patent related to a liquid container with flexible walls, tried to pay the fees on the day it filed its petition but didn’t have enough money in its account. The Patent and Trademark Office’s electronic filing system sent a message saying that the payment hadn’t cleared, but Luv’n Care didn’t make its payment until April 11, 2017, 10 days later.
Because a petition doesn’t get a filing date until it’s filed and the full fee paid—meaning received and not just tendered—Luv’n Care’s petition wasn’t officially filed until April 11, more than a year after it was served with a complaint in district court, the board said.
The second decision involves Amneal Pharms. LLC’s plans to introduce a generic version of Endo Pharms Inc.’s crush-resistant opioid pill. Endo in Nov. 2012 sued Amneal for infringing other patents covering the drug but not U.S. Patent No. 8,329,216, which was the patent challenged in the IPR.
On Jan. 9, 2013, Endo asked for permission to add infringement allegations involving the ‘216 patent, and in its moving papers included a copy of the proposed new complaint. The court granted the request, and Endo filed and served Amneal the new complaint on Jan. 17, 2013. Amneal’s IPR, filed Jan. 14, 2014, was within the one-year deadline, the PTAB said.
Endo argued that the one-year deadline started when it moved to amend its complaint on Jan. 9, because it served that motion on Amneal with a copy of the proposed amended complaint. However, the PTAB rejected the argument, because the complaint wasn’t served until Jan. 17. Endo only served a proposed amended complaint on Jan. 9, and Amneal wasn’t officially sued for infringing the patent until Jan. 17, the PTAB said.
Judge Lynne H. Browne wrote the decision in Luv’n Care v. McGinley, which Judges Susan L. C. Mitchell and James J. Mayberry joined. Erickson Kernell IP LLC represented McGinley, while Nubylaw represented McGinley.
Judge Jacqueline Wright Bonilla wrote the decision in Amneal Pharms. LLC v. Endo Pharms. Inc., which Judges Toni R. Scheiner and Francisco C. Prats joined. Sterne, Kessler, Goldstein & Fox PLLC represented Amneal, while Mayer Brown LLP represented Endo.
The cases are Luv’n Care Ltd v. McGinley , P.T.A.B., No. IPR2017-01216, designated informative 1/10/18 and Amneal Pharms. LLC v. Endo Pharms. Inc. , P.T.A.B., No. IPR2014-00360, designated informative 1/10/18 .
To contact the reporter on this story: Peter Leung in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Mike Wilczek at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)